Exelixis
EXEL Nasdaq· Biotechnology
Last close · Oct 27, 2026
$65.35
KIRA · Stoqly’s AI analyst, in plain words
- Exelixis had $2.3B of revenue in fiscal 2025, up 7.0% on the year before. Over five years, revenue changed +18.6% a year on average.
- Its operating margin was 37.6%, up 9.7 pts: of every 100 in sales, about 38 is left after running the business.
- Exelixis made $783M of net profit in fiscal 2025.
- Free cash flow was $876M in fiscal 2025, 37.8% of revenue.
- Exelixis returned $948M to shareholders in fiscal 2025, 108% of free cash flow. The diluted share count fell 4.8%.
- Exelixis has $1.1B more cash than debt.
Market cap
$17.0B
P/E
20.6x
Revenue
$2.3B
Net income
$783M
Free cash flow
$876M
Operating margin
37.6%
Exelixis in 30 seconds · fiscal 2025
Are sales growing?
+7.0%
Yes. Sales grew 7.0% last year.
Does it make a profit?
33.7%
Yes. It keeps 33.7% of every sale as profit.
Does profit turn into cash?
37.8%
Yes. 37.8% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
How is the share priced?
20.6x
One share costs 20.6 times its yearly profit per share. Typical for its sector: 28.4x.
What Exelixis does
No business description yet.
- Fiscal year ends
- January 2, 2026
- Latest annual report
- 10-K · Feb 10, 2026
- Legal name
- Exelixis Inc
- CIK
- 0000939767
Exelixis · EXEL
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.4B | $1.6B | $1.8B | $2.2B | $2.3B |
| Revenue growth | 45.3% | 12.3% | 13.6% | 18.5% | 7.0% |
| Gross margin | 96.3% | 96.4% | 96.0% | 96.5% | 96.4% |
| Operating margin | 20.0% | 12.5% | 9.3% | 27.9% | 37.6% |
| Net income | $231M | $182M | $208M | $521M | $783M |
| Net margin | 16.1% | 11.3% | 11.4% | 24.0% | 33.7% |
| Diluted EPS | $0.72 | $0.56 | $0.65 | $1.76 | $2.78 |
| Cash | |||||
| Cash from operations | $401M | $363M | $333M | $700M | $884M |
| Capital expenditure | $54.2M | $27.7M | $40.5M | $28.4M | $8.4M |
| Free cash flow | $347M | $335M | $293M | $672M | $876M |
| FCF margin | 24.2% | 20.8% | 16.0% | 31.0% | 37.8% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $0.0M | $0.0M | $550M | $652M | $948M |
| Share count change | 1.4% | 0.7% | −1.0% | −7.9% | −4.8% |
| Debt and strength | |||||
| Cash and short-term investments | $1.5B | $1.3B | $995M | $1.1B | $1.1B |
| Debt incl. finance leases | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $2.2B | $2.5B | $2.3B | $2.2B | $2.2B |
| Net debt / EBITDA | −4.9x | −5.9x | −5.1x | −1.8x | −1.2x |
| Current ratio | 5.4x | 5.0x | 3.3x | 3.6x | 3.6x |
| Returns and quality | |||||
| Return on capital | 31.8% | 16.3% | 11.3% | 38.5% | 64.9% |
| Return on equity | 11.3% | 7.8% | 8.7% | 23.1% | 35.5% |
| Piotroski F-score | 5 | 4 | 4 | 8 | 6 |
| Altman Z'' | 9.9 | 7.7 | 5.8 | 7.0 | 7.7 |
Insiders bought, 12 months
$1.2M
1 insider
Insiders sold, 12 months
$42.2M
12 insiders
Of sales under plans
16%
$6.9M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Exelixis · EXEL
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Exelixis EXEL | $17.0B | 7.0% | 37.6% | 37.8% | 64.9% | 20.6x | 6 |
| Fortrea FTRE | $2.3B | 1.0% | −32.0% | 3.2% | −36.2% | — | — |
| Moderna MRNA | $82.8B | −39.9% | −158.1% | −106.2% | −65.4% | — | 2 |
| Neurocrine Biosciences NBIX | $15.2B | 21.5% | 21.6% | 26.2% | 25.6% | 21.4x | 6 |
| United Therapeutics UTHR | $27.1B | 10.6% | 46.9% | 32.7% | — | 21.2x | — |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $65.35 a share, the company is worth $17.0B: 20.6 times its earnings of the last four quarters.
Exelixis grew sales faster than 2 of its 4 similar companies. Its P/E is higher than 0 of 2.
Source: SEC EDGAR XBRL filings (CIK 0000939767). Data updated October 14, 2026. For information only — not investment advice. Check the original filings before relying on any figure.